By Liz Moyer Investing.com -- Tech stocks were rallying on Friday after better-than-expected subscriber numbers from Netflix and cost-cutting by Google parent Alphabet. Here are...
By Scott Kanowsky Investing.com -- Shares in Eli Lilly and Company (NYSE:LLY) dipped in early trading on Friday after the U.S. Food and Drug Administration decided not to give...
By Deena Beasley San Francisco (Reuters) - Drugmakers are prioritizing complex biotech medicines over treatments that can be given as pills because recent U.S. legislation gives...
Things should start returning to normal this week, with a ton of economic data and the December FOMC minutes. The data dump doesn’t begin until Wednesday, with the ISM...
The U.S. stock market is on track for its worst year since 2008, with the S&P 500 down 19.6% year-to-date. The market’s trajectory in 2023 will continue to be dictated by...
Biogen stock is getting favorable ratings after successful trial results for its latest Alzheimer's treatment Lecanemab is Biogen's latest attempt to cure the disease after its...
Eli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.
| Average | 378.18 (+9.28% Upside) |
| High | 440.00 |
| Low | 202.00 |
| Price | 346.07 |
| No. of Analysts | 24 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Sell | Buy |
| Technical Indicators | Strong Buy | Buy | Strong Sell | Strong Sell | Strong Buy |
| Summary | Strong Buy | Neutral | Strong Sell | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 133.42 | 133.51 | 127.35 | +6.25 | +4.91% | 137.60M | NASDAQ | |||
| 8.06 | 8.13 | 7.79 | -0.12 | -1.47% | 7.80M | NYSE | |||
| 99.28 | 99.42 | 95.91 | +5.37 | +5.72% | 53.17M | NASDAQ | |||
| 6.49 | 6.55 | 6.06 | +0.11 | +1.72% | 13.42M | NYSE | |||
| 139.37 | 139.94 | 134.61 | +3.22 | +2.37% | 28.53M | NASDAQ | |||
| 342.50 | 344.00 | 332.63 | +26.72 | +8.46% | 27.20M | NASDAQ | |||
| 240.22 | 240.74 | 234.51 | +8.29 | +3.57% | 34.98M | NASDAQ | |||
| 9.40 | 9.88 | 9.03 | +0.45 | +5.03% | 20.00M | NYSE | |||
| 4.03 | 4.36 | 3.93 | -0.140 | -3.36% | 1.20M | NASDAQ | |||
| 53.70 | 54.00 | 53.70 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 106.14 | 106.21 | 101.75 | +4.24 | +4.16% | 4.96M | NYSE | |||
| 93.08 | 93.17 | 90.61 | +1.28 | +1.39% | 1.05M | NYSE | |||
| 30.99 | 31.07 | 30.53 | +0.45 | +1.47% | 886.09K | NYSE | |||
| 46.78 | 46.83 | 45.67 | +0.32 | +0.69% | 21.79M | NASDAQ | |||
| 0.39 | 0.41 | 0.35 | +0.03 | +6.85% | 1.62M | NASDAQ |